# Molecular Cancer Therapeutics

## Table of Contents

### Highlights of This Issue 1019

#### REVIEW

1021  Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors  
Rodrigo Dienstmann, Jordi Rodon, Violeta Serra, and Josep Tabernero

#### SMALL MOLECULE THERAPEUTICS

1032  Enhancement of Nab-Paclitaxel Antitumor Activity through Addition of Multitargeting Antiangiogenic Agents in Experimental Pancreatic Cancer  
Niranjan Awasthi, Changhua Zhang, Anna M. Schwarz, Stefan Hinz, Margaret A. Schwarz, and Roderich E. Schwarz

1044  The Phosphoinositide 3-Kinase α Selective Inhibitor BYL719 Enhances the Effect of the Protein Kinase C Inhibitor AEB071 in GNAQ/GNA11-Mutant Uveal Melanoma Cells  
Elgilda Musi, Grazia Ambrosini, Elisa de Stanchina, and Gary K. Schwartz

1054  Centmitor-1, a Novel Acridinyl-Acetohydrazide, Possesses Similar Molecular Interaction Field and Antimitotic Cellular Phenotype as Rigosertib, ON 01910.Na  

1067  Preclinical Evaluation of the Supercritical Extract of Azadirachta Indica (Neem) Leaves In Vitro and In Vivo on Inhibition of Prostate Cancer Tumor Growth  
Qiangu Wu, Manish Kohli, H. Robert. Bergen III, John C. Cheville, R. Jeffrey Karmes, Hong Cao, Charles Y.F. Young, Donald J. Tindall, Mark A. McNiven, and Krishna Vanaja Donkena

1078  Characterization of the Activity of the PI3K/mTOR Inhibitor XL765 (SAR245409) in Tumor Models with Diverse Genetic Alterations Affecting the PI3K Pathway  

1092  UPARANT: A Urokinase Receptor–Derived Peptide Inhibitor of VEGF-Driven Angiogenesis with Enhanced Stability and In Vitro and In Vivo Potency  
Maria Vincenza Carriero, Katia Bifulco, Michele Minopoli, Liliana Lista, Ornella Maglio, Luigi Mele, Gioconda Di Carluccio, Mario De Rosa, and Vincenzo Pavone

1105  Preclinical Pharmacological Evaluation of a Novel Multiple Kinase Inhibitor, ON123300, in Brain Tumor Models  
Xiaoping Zhang, Hua Lv, Qingyu Zhou, Rana Elkhohi, Jerry E. Chipuk, M.V. Ramana Reddy, E. Premkumar Reddy, and James M. Gallo

1117  Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials  

1130  Protein Kinase D as a Potential Chemotherapeutic Target for Colorectal Cancer  
Ning Wei, Edward Chu, Peter Wipf, and John C. Schmitz
CANCER BIOLOGY AND SIGNAL TRANSDUCTION

1142 Highly Active Combination of BRD4 Antagonist and Histone Deacetylase Inhibitor against Human Acute Myelogenous Leukemia Cells
See related article, p. 1194

1155 Combination of Imatinib with CXCR4 Antagonist BKT140 Overcomes the Protective Effect of Stroma and Targets CML In Vitro and In Vivo
Katia Beider, Merav Darash-Yahana, Orly Blaier, Maya Koren-Michowitz, Michal Abraham, Hanna Wald, Ori Wald, Eithan Galun, Orly Eizenberg, Amnon Peled, and Arnon Nagler

1170 The Use of Olaparib (AZD2281) Potentiates SN-38 Cytotoxicity in Colon Cancer Cells by Indirect Inhibition of Rad51-Mediated Repair of DNA Double-Strand Breaks
Makiko Tahara, Takeshi Inoue, Futoshi Sato, Yasuyuki Miyakura, Hisanaga Horie, Yoshikazu Yamasaki, Hirofumi Fujii, Kenjirou Kotake, and Kokichi Sugano

1181 A Novel Temozolomide–Perillyl Alcohol Conjugate Exhibits Superior Activity against Breast Cancer Cells In Vitro and Intracranial Triple-Negative Tumor Growth In Vivo

1217 Ponatinib Induces Apoptosis in Imatinib-Resistant Human Mast Cells by Dephosphorylating Mutant D816V KIT and Silencing β-Catenin Signaling
Bei Jin, Ke Ding, and Jingxuan Fan

1231 PIM Kinases Are Essential for Chronic Lymphocytic Leukemia Cell Survival (PIM2/3) and CXCR4-Mediated Microenvironmental Interactions (PIM1)

1246 Pharmacologic Suppression of JAK1/2 by JAK1/2 Inhibitor AZD1480 Potently Inhibits IL-6–Induced Experimental Prostate Cancer Metastases Formation
Lei Gu, Pooja Talati, Paraskevi Vogiatzi, Ana L. Romero-Weaver, Junaid Abdulghani, Zhuyong Liao, Benjamin Leiby, David T. Hoang, Tuomas Mirtti, Kalle Alamen, Michael Zinda, Dennis Huszar, and Marja T. Nevalainen

1259 Hedgehog Pathway Inhibition in Chondrosarcoma Using the Smoothened Inhibitor IPI-926 Directly Inhibits Sarcoma Cell Growth

1270 Epithelial-to-Mesenchymal Transition Mediates Docetaxel Resistance and High Risk of Relapse in Prostate Cancer
Mercedes Marín-Aguilera, Jordi Codony-Servat, Óscar Reig, Juan José Lozano, Pedro Luis Fernández, María Verónica Pereira, Natalia Jiménez, Michael Donovan, Pere Puig, Lourdes Mengué, Raquel Bermudo, Albert Font, Enrique Gallardo, María José Ribal, Antonio Alcaraz, Pere Gascón, and Begoña Mellado

1285 Identification of Transmembrane Protein 98 as a Novel Chemoresistance-Conferring Gene in Hepatocellular Carcinoma
Kevin Tak-Pan Ng, Chung Mau Lo, Dong Yong Guo, Xiang Qi, Chang Xian Li, Wei Geng, Xiao Bing Liu, Chang Chun Ling, Yuen Yuen Ma, Wai Ho Yeung, Yan Shao, Ronnie Tung-Ping Poon, Sheung Tat Fan, and Kwan Man
Table of Contents

1298  Aurora Kinase Inhibition Induces PUMA via NF-κB to Kill Colon Cancer Cells  
      Jing Sun, Kyle Knickelbein, Kan He, Dongshi Chen,  
      Crissy Dudgeon, Yongqian Shu, Jian Yu, and Lin Zhang

1309  Nuclear Translocation of Hand-1 Acts as a Molecular Switch to Regulate Vascular  
      Radiosensitivity in Medulloblastoma  
      Tumors: The Protein uPAR Is a Cytoplasmic Sequestration Factor for Hand-1  
      Swapna Asuthkar, Venkateswara Rao Gogineni,  
      Jasti S. Rao, and Kiran Kumar Velpula

1323  The G Protein–Coupled Receptor GALR2 Promotes Angiogenesis in Head and Neck  
      Cancer  
      Rajat Banerjee, Elizabeth A. Van Tubergen,  
      Christina S. Scanlon, Robert Vander Broek,  
      Joel P. Lints, Min Liu, Nickole Russo,  
      Ronald C. Inglehart, Yugang Wang,  
      Peter J. Polverini, Keith L. Kirkwood, and  
      Nisha J. D’Silva

1334  The Role of Gene Body Cytosine Modifications in MGMT Expression and  
      Sensitivity to Temozolomide  
      Erika L. Moen, Amy L. Stark, Wei Zhang,  
      M. Eileen Dolan, and Lucy A. Godley

1345  ERBB3/HER2 Signaling Promotes Resistance to EGFR Blockade in Head and Neck and  
      Colorectal Cancer Models  
      Li Zhang, Carla Castanaro, Bo Luan, Katie Yang,  
      Liangfen Fan, Jeanette L. Fairhurst,  
      Ashique Rafique, Terra B. Potocky, Jing Shan,  
      Frank J. Dellino, Ergang Shi, Tammy Huang,  
      Joel H. Martin, Gang Chen, Douglas MacDonald,  
      John S. Rudge, Gavin Thurston, and  
      Christopher Daly

1356  Nuclear Epidermal Growth Factor Receptor Is a Functional Molecular Target in Triple-  
      Negative Breast Cancer  
      Toni M. Brand, Mari Iida, Emily F. Dunn,  
      Neha Luthar, Kellie T. Kostopoulos,  
      Kelsey L. Corrigan, Matthew J. Wiekloński,  
      David Yang, Kari B. Wisinski, Ravi Salgia, and  
      Deric L. Wheeler

1369  Metallothionein 1G and Zinc Sensitize Human Colorectal Cancer Cells to  
      Chemotherapy  
      Juan M. Arriaga, Angela Greco, José Mordoh, and  
      Michele Bianchini

COMPANION DIAGNOSTICS AND CANCER BIOMARKERS

1382  Concordance of Genomic Alterations between Primary and Recurrent Breast  
      Cancer  
      Funda Meric-Bernstam, Garrett M. Frampton,  
      Jaime Ferrer-Lozano, Roman Yelensky,  
      Jose A. Perez-Fidalgo, Ying Wang, Gary A. Palmer,  
      Jeffrey S. Ross, Vincent A. Miller, Xiaoping Su,  
      Pilar Eroles, Juan Antonio Barrera, Octavio Burgues,  
      Ana M. Lluch, Xiaofeng Zheng, Aysegul Sahin,  
      Philip J. Stephens, Gordon B. Mills,  
      Maureen T. Cronin, and Ana M. Gonzalez-Angulo

AC icon indicates Author Choice
For more information please visit www.aacrjournals.org
ABOUT THE COVER

Angiogenesis is important for tumor progression. In squamous cell carcinoma of the head and neck (SCCHN), angiogenesis is activated by cytokines including IL-6 and VEGF. Galanin receptor 2 (GALR2) is a G protein-coupled receptor that induces aggressive growth in SCCHN. GALR2 stimulates tumor angiogenesis in SCCHN via p38-mediated inhibition of tristetraprolin (TTP) with resultant enhanced cytokine secretion. Given that p38 inhibitors are in clinical use for inflammatory disorders, GALR2/p38-mediated cytokine secretion may be an excellent target for new adjuvant therapy in SCCHN. For details, see article by Banerjee, Van Tubergen, and colleagues on page 1323.
Molecular Cancer Therapeutics

13 (5)


| Updated version | Access the most recent version of this article at: http://mct.aacrjournals.org/content/13/5 |

| E-mail alerts | Sign up to receive free email-alerts related to this article or journal. |
| Reprints and Subscriptions | To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org. |
| Permissions | To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org. |